# Verana Health

> Verana Health curates de-identified clinical records into disease-specific datasets, research services, and software for life sciences companies, contract research organizations, clinicians, and medical societies. Its registry relationships and 2026 COTA merger connect specialty data with trial planning, recruitment, outcomes research, and commercialization.

- **Founded:** 2018
- **Headquarters:** San Francisco, United States
- **Founders:** Mark Blumenkranz (Co-founder; ophthalmologist and advisor), David W. Parke II (Co-founder; executive chairman), Miki Kapoor (Co-founder; former CEO)
- **Products:** VeraQ, Qdata, Qdata Explorer, Site Explorer, Verana Trial Connect
- **Notable:** At the January 2026 merger, reported combined access to over 95 million patients, over 20,000 contributing clinicians, and over 30 academic medical centers., A published Syneos/EyePoint case reported 31 active trial sites identified in five weeks, 15 VTC activations, and 27 patients screened., IRIS Registry data available through Qdata Explorer included 11 years of longitudinal data as of May 2025.

## Products & services

- **VeraQ** — Clinician-directed, AI-enhanced platform for ingesting, harmonizing, and curating clinical data.
- **Qdata** — Research-ready, disease-specific datasets across specialty therapeutic areas.
- **Qdata Explorer** — Cloud application for exploring ophthalmology cohorts without coding.
- **Site Explorer** — Protocol modeling and site identification using registry-derived clinical data.
- **Verana Trial Connect** — Secure software that helps participating practices prescreen their own patients against trial criteria.
- **Agent Claire for Life Sciences** — Conversational access to disease-specific data, with underlying SQL for review.
- **MIPS Advisory Services** — Quality reporting assistance for participating medical practices.
- **Real-world evidence research** — Services supporting outcomes research, treatment patterns, safety, health economics, and commercial insights.

## Achievements

- At the January 2026 merger, reported combined access to over 95 million patients, over 20,000 contributing clinicians, and over 30 academic medical centers.
- A published Syneos/EyePoint case reported 31 active trial sites identified in five weeks, 15 VTC activations, and 27 patients screened.
- IRIS Registry data available through Qdata Explorer included 11 years of longitudinal data as of May 2025.

## Latest updates

- **2026-01** — Announced COTA merger and $52 million in additional equity commitments.
- **2026-09** — Launched Agent Claire for Life Sciences with conversational data queries and SQL output.
- **2026-10** — Announced Bitfount collaboration for combined imaging and EHR prescreening.

## Links

- Website: https://veranahealth.com/
- LinkedIn: https://www.linkedin.com/company/verana-health/
- Twitter/X: https://twitter.com/veranahealth
- Facebook: https://facebook.com/veranahealth

---

Profile page: https://yespress.io/verana-health
Published by YesPress — https://yespress.io
Last updated: 2026-10-16